Dive Brief:

简报：

GSK will pay privately held Empirico

GSK将支付给私营的Empirico公司

$85 million

8500万美元

for the rights to an experimental therapy that may treat a range of patients with chronic obstructive pulmonary disease, or COPD.

对于可能治疗慢性阻塞性肺病（COPD）的一系列患者的实验性疗法的权利，

Empirico is currently testing the drug, known as EMP-012, in a Phase 1 clinical trial. Once that research is complete, GSK will take over development and handle regulatory filings and marketing if the medicine wins approval, the two companies said Tuesday.

Empirico 公司目前正在对名为 EMP-012 的药物进行一期临床试验。两家公司周二表示，一旦该研究完成，如果该药物获得批准，GSK 将接手开发并负责监管申报和营销工作。

As part of the deal, Empirico may receive payments of as much as $660 million more from GSK if the drug reaches certain development, regulatory and commercial milestones. Empirico will also be eligible for tiered royalties on worldwide sales.

作为协议的一部分，如果该药物达到某些开发、监管和商业里程碑，Empirico 可能会从 GSK 获得高达 6.6 亿美元的额外付款。Empirico 还将有资格获得全球销售的分层特许权使用费。

Dive Insight:

潜水洞察：

GSK is already a major player in the respiratory market with well-known drugs including Advair and Trelegy Ellipta that are used to treat both asthma and COPD. In recent years, it’s been making a concerted effort to build up its COPD pipeline, striking a major alliance with

GSK已经在呼吸系统市场占据重要地位，拥有包括Advair和Trelegy Ellipta在内的知名药物，这些药物用于治疗哮喘和慢性阻塞性肺病（COPD）。近年来，GSK一直在努力加强其COPD产品线，并与一家公司达成了重要联盟。

Hengrui Pharma

恒瑞医药

in July that came with a COPD medication.

七月的时候，伴随着一种COPD药物而来。

The British drugmaker also fought through an

英国制药商也经历了一场战斗

initial rejection

初始拒绝

of a bid to expand the use of its Nucala medicine to include COPD patients in 2018. After conducting another

于2018年试图扩大其Nucala药物的使用范围以包括COPD患者。在进行了另一项

major study in COPD

慢性阻塞性肺疾病的重要研究

, GSK finally won approval of the

，GSK最终获得了批准

expanded label

扩展标签

for Nucala earlier this year.

今年早些时候，Nucala获批。

COPD is a fast-growing market with not enough successful treatments, GSK and Empirico say. They cited research suggesting that as many as 600 million people will suffer from the disease by 2050, with the condition becoming the leading cause of all hospital admissions.

GSK和Empirico表示，COPD市场增长迅速，但缺乏足够的成功治疗方法。他们引用的研究表明，到2050年，将有多达6亿人患上这种疾病，该病将成为所有住院治疗的首要原因。

Empirico’s drug is especially attractive because it has the potential to treat “a broad spectrum” of COPD patients, the companies say. Nucala and

Empirico的药物特别有吸引力，因为该公司称其有可能治疗“广泛的”COPD患者。Nucala和

Regeneron and Sanofi’s Dupixent

再生元和赛诺菲的Dupixent

– the first biologic approved to treat COPD – focus on a subset of patients.

——首个获批用于治疗COPD的生物制剂——专注于一部分患者。

EMP-012 is an oligonucleotide designed to modulate gene expression. The drug targets an inflammatory pathway implicated in COPD that isn’t related to any specific risk factor, such as smoking, co-morbid disease or the “type 2 inflammation” Dupixent specifically disrupts. The companies said the medicine has potential as both a COPD monotherapy and as part of a combination with other GSK therapies..

EMP-012是一种旨在调控基因表达的寡核苷酸药物。该药物靶向一种与慢性阻塞性肺病（COPD）相关的炎症通路，这种通路与任何特定风险因素（如吸烟、合并症或Dupixent专门针对的“2型炎症”）无关。公司表示，这种药物既可作为COPD的单一疗法，也可与GSK其他疗法联合使用，具有潜在价值。